Teva’s Ongavia (biosimilar, ranibizumab) Receives the MHRA’s Approval for the Treatment of Eye Diseases
- The MHRA has approved Ongavia, a biosimilar referencing Lucentis for multiple ophthalmic conditions
- Ongavia is also licensed for the treatment of visual impairment due to DME, PDR, visual impairment due to macular oedema secondary to RVO & visual impairment due to CNV. In the P-III (COLUMBUS-AMD) study, Teva's biosimilar ranibizumab is highly similar to its reference Lucentis in terms of clinical efficacy, ocular & systemic safety for AMD & additional indications
- Under the agreement with Bioeq AG, Teva will have exclusive commercialization rights for ranibizumab biosimilar in the UK, EU & Canada. The biosimilar is under EC’s review & submission is expected to be completed in late 2022 for Canadian approval
Ref: Businesswire | Image: Teva
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
